NEWS
PRESS RELEASES
28 08, 2020

ROMARK ANNOUNCES FDA APPROVAL OF NEW MANUFACTURING FACILITY IN MANATI, PUERTO RICO

2020-08-28T10:51:31-04:00August 28th, 2020|Categories: COVID-19 Posts, Press Releases|

TAMPA, Fla. - August 20, 2020 – Romark, a research-based pharmaceutical company focused on the discovery, development and delivery of innovative new medicines, primarily in the field of infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has approved the company's manufacturing facility in Manati, Puerto Rico for the production of ALINIA® (nitazoxanide)

11 08, 2020

ROMARK INITIATES NEW PHASE 3 CLINICAL TRIAL OF NT-300 FOR THE TREATMENT OF COVID-19

2020-08-11T10:07:06-04:00August 11th, 2020|Categories: COVID-19 Posts, Press Releases|

NT-300 clinical program now comprises three pivotal trials for COVID-19   TAMPA, Fla. – August 11, 2020 – Romark, a research-based pharmaceutical company focused on the discovery, development and delivery of innovative new medicines, primarily in the field of infectious diseases, announced today the initiation of a Phase 3 clinical trial of its investigational new drug

24 06, 2020

ROMARK INITIATES PHASE 3 CLINICAL TRIALS OF NT-300 FOR COVID-19

2020-06-25T16:45:53-04:00June 24th, 2020|Categories: COVID-19 Posts, Press Releases|

Clinical Development Program for NT-300 Includes Trials Addressing Prevention and Treatment of COVID-19 and Other Viral Respiratory Illnesses   TAMPA, Fla. – April 27, 2020 – Romark announced today it will initiate two clinical trials of its investigational new drug candidate NT-300 (nitazoxanide extended-release tablets) for prevention of COVID-19 and other viral respiratory illnesses in high-risk